Company ProfilePremium

Health and Happiness (H&H) International Holdings Limited

Company Profile Analysis

Ticker: 1112.HK健合

ESOMAR 23 Corporate BadgeISO Certifications Badge
Health and Happiness (H&H) International Holdings Limited - Company showcase

Year Founded & Workforce

1999

2,800 Employees

Health and Happiness (H&H) International Holdings Limited logo

Health and Happiness (H&H) International Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Health and Happiness (H&H) International Holdings Limited Overview

H&H Group is a Hong Kong-listed, China-centric premium family nutrition company. It has repositioned from a single-category Chinese infant formula and probiotics player (Biostime) into a three-pillar global portfolio:

Adult Nutrition & Care (ANC): Swisse, the No. 1 VHMS brand in both Chinese mainland and Australia.

Baby Nutrition & Care (BNC): Biostime super-premium infant milk formula (IMF), paediatric probiotics and supplements.

Pet Nutrition & Care (PNC): Zesty Paws and Solid Gold, anchored in the US.

The business model is asset-light: brand, formulation, regulatory licensing and channel orchestration, with predominantly outsourced manufacturing. It has structurally high gross margins of 60–65% but heavy advertising and promotion intensity of about 38–42% of revenue. The investment case turns on three things:

  • whether the 2025–26 recovery in Biostime IMF share is durable, helped in 2026 by competitor recalls;

  • whether Swisse can keep growing in China's cross-border and Douyin channels;

  • whether management can complete the deleveraging begun after the debt-funded US$610M Zesty Paws acquisition. Net leverage fell from 3.99x at end-2024 to 2.05x at 30 June 2026.


Company's own description (FY2025 annual results, Note 1): The Group is "principally engaged in the manufacture and sale of premium paediatric nutrition, baby care products, adult nutrition and care products and pet nutrition and care products." The Chairman's framing since 2023 is to become "a global leader in premium family nutrition and wellness with superior products and aspirational brands." B Lab (2024) summarises the mission as making millions of people and their pets healthier and happier.

Independent characterisation. H&H is best understood as a branded consumer-health platform with three economically distinct engines:

  1. ANC (48.4% of FY2025 revenue). A VHMS (vitamins, herbal and mineral supplements) franchise built on the Swisse brand, acquired in 2015.

    • About 70.7% of ANC revenue comes from Chinese mainland (FY2025). Roughly 82% of that is sold through cross-border e-commerce (CBEC), with the balance through "blue hat"-registered normal trade.

    • The Australian domestic market is about 11% of group revenue.

    • Thirteen expansion markets (Singapore, Hong Kong, Italy, Thailand, Malaysia, Indonesia, India, the Middle East and others) contributed 6.9% of ANC sales in FY2025 and 7.8% in H1 2026.

    • This is the highest-margin engine: segment gross margin was 67.9% in FY2025 and 70.2% in H1 2026.

  2. BNC (36.6% of FY2025; 41.8% of H1 2026). Biostime super-premium IMF (mostly imported French-made formulas, including goat-milk and organic), paediatric probiotics (No. 1 in China), kids' nutritional supplements, and residual baby food and care (Good Goût, Dodie).

    • Revenue is overwhelmingly Chinese mainland (97% of FY2025 IMF revenue), sold through mother-and-baby specialty stores, e-commerce and Douyin.

    • This engine is exposed to China's birth-rate decline and to the SAMR "new GB" registration regime, which required re-registration of every IMF series by 2023. H&H completed its transition by June 2025.

  3. PNC (15.0% of FY2025). Zesty Paws, a multi-condition pet supplement brand and the high-margin growth driver, and Solid Gold, a holistic pet food brand being premiumised.

    • North America is 80% of PNC revenue (FY2025), sold through Amazon, Chewy, Walmart, PetSmart, Petco, Tractor Supply, Target and others.

    • Chinese mainland PNC is being restructured toward locally made, higher-margin product.

Revenue model. Revenue is 100% product sales ("sale of goods", recognised at a point in time). There is no material service, subscription or licensing revenue. Mainland China business customers usually pay in advance; overseas customers receive 30–90 day credit terms. Sales rebates and returns create variable consideration (refund liabilities of RMB635.9M at 30 June 2026). No single customer exceeds 10% of revenue.

Value chain position. H&H sits at the brand-owner and marketer layer:

Upstream: formulation, R&D and clinical substantiation (R&D is only 1.2–1.9% of revenue), regulatory registration (China GB formula registration, blue-hat health food licences, cross-border filings), and procurement of ingredients and contract manufacturing. Key IMF supply comes from French dairy partners, including Isigny Sainte Mère (ISM), in which H&H holds an investment.

Downstream: omni-channel distribution (CBEC platforms Tmall Global and JD International, Douyin, Sam's Club, baby specialty stores, pharmacies, Australian grocery and pharmacy, US pet specialty and mass retail).

  • PP&E is only RMB302.8M against total assets of RMB19.4bn (FY2025). Goodwill and intangibles are RMB12.7bn, or 65% of total assets.

Customer types and end-markets.

  • End consumers: Chinese urban middle-class parents (IMF/probiotics), health-conscious adults and ageing consumers (VHMS, NAD+, cellular nutrition, heart and liver health), and pet parents (US, China).

  • Trade customers: e-commerce platforms, distributors, mother-and-baby chains, pharmacy chains, grocery, pet specialty and mass merchandisers.

  • End-markets: China IMF (about RMB185bn in 2025 per Daxue Consulting, cited by Reuters), China VHMS, Australian VMS, US pet supplements and pet food.

Strategy

Stated strategic themes

FY2023 strategic objectives (Chairman's Statement):

  1. Drive growth in high-margin nutritional supplements.

  2. Maintain healthy profitability and share in super-premium IMF.

  3. Win in core markets: ANC in China and ANZ, PNC in North America.

  4. Invest in the future by expanding into new markets.

  5. Optimise the capital structure.

FY2022 framing: "Winning in Core, Globalisation and Diversification, and Investing in the Future," plus the "PPAE" brand model (Premium, Proven, Aspirational, Engaging).

FY2025 / 2026 outlook themes:

  • Grow high-margin, fast-growing nutritional supplements while delivering healthy profitability.

  • Consolidate Swisse's No. 1 position in China.

  • Prioritise Douyin and new retail channels.

  • Scale the thirteen expansion markets using the Singapore and Hong Kong playbook.

  • Sustain IMF momentum through new-mother education and Stage 3 conversion, and extend into broader children's nutrition.

  • Lift Solid Gold's high-margin mix above 37%.

  • Complete China pet supply localisation by end-2026.

  • Continue deleveraging and raise the share of RMB debt.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetail / target
Group-wide B Corp certificationOct 2024Score 92.5; achieved ahead of the 2025 target
Capital structure refinancingJan 2025US$300M 9.125% senior notes due 2028 replaced the 13.5% notes due 2026
Corporate daigou deprioritisationMid-2025Strategic exit from a low-quality export channel in ANZ
New-GB IMF transition completeJun 2025All series relaunched under new GB
Douyin / new-retail channel push2025–26Douyin +71.4% (2025), +57.5% (H1 2026); Sam's Club +29.7% / +34.2%
Swisse Plus cellular nutrition and Little Swisse "mega-brand"2025–26Swisse Plus +18.6%; Little Swisse +60.2% (H1 2026)
Swisse Nutra (premium beauty) launchH1 2026Asia expansion markets
Biostime HMO IMF launchH1 2026Described as the first imported HMO IMF in China; H2 2026 marketing step-up
Solid Gold China supply localisation2025–end-2026Response to US–China tariffs
Solid Gold US premiumisation and channel optimisationCompleted 2025High-margin mix about 37%; returned to growth in H1 2026
European restructuring (Good Goût / Dodie)2,025RMB29.8M one-time costs; RMB106.5M impairment
Group entity structure optimisation2024–25One-time consulting fees of RMB17.0M (2024) and RMB19.8M (2025)
Debt reduction2025–26Gross debt down more than RMB600M (2025) and more than RMB1bn (H1 2026); about RMB1.2bn of USD term-loan prepayments in H1 2026 and RMB300M on 13 Aug 2026; RMB / RMB-hedged debt at 97.8% of borrowings (Jun 2026)
Term loan refinancing5 Aug 2026About US$320M term loan plus a US$10M RCF to refinance 2027 maturities
Dividend policy reset upwardAug 2026Interim payout 50% of adjusted net profit (vs 30% for FY2025)

Medium-term targets and guidance

  • No numeric multi-year revenue or margin targets are disclosed by the company.

  • Qualitative 2026 guidance: "continued growth with consistent underlying full-year profitability despite macro challenges", with higher H2 2026 marketing investment.

  • Historical dividend policy: about 50% of adjusted net profit (stated in FY2022), lowered to about 30% for FY2024–25 during deleveraging, and returned to 50% at the 2026 interim.

  • Historical aspiration: a 2023 China revenue target of RMB10bn (cut from an earlier RMB20bn aspiration, per Jiemian media). This is not a current formal target.

Products & Services

Pricing models: all products are sold at retail and wholesale list prices. List prices and price architecture are not publicly disclosed in filings, so SKU-level pricing is "not publicly disclosed" unless noted.

ANC — Adult Nutrition & Care

Brand / lineDescription and capabilitiesTarget customerLaunch / latestFlagships and notes
Swisse (Core)Australian-origin VHMS: multivitamins, beauty-from-within (hair/skin/nails), liver detox (milk thistle), heart health, joint health, immunity, sleep and stress, magnesiumMass-premium adults, China and ANZAcquired 2015; continuous NPDSwisse Liver Cleanse leads the high-end milk thistle segment in China e-commerce (FY2023). Swisse Magnesium Glycinate is a 2025 ANZ hit. Swisse revenue reached US$1bn net sales in FY2025 (company). No. 1 in China overall VHMS (Kantar, FY2025) and No. 1 Australia VMS (IQVIA)
Swisse Plus / Plus+Premium "cellular nutrition" and anti-ageing tier: NAD+ range, metabolism, heart healthAgeing, affluent consumers (China)2022 (NAD+), expandingNAD+ ranked No. 2 in China e-commerce NAD+ (Early Data, 2023). Double-digit share of China ANC revenue (2023). +18.6% growth in H1 2026
Little SwisseKids' supplements, including Kids GummiesParents of children aged 3+c.2023; ANZ Kids Gummies 2025+60.2% in H1 2026
Swisse MeFunctional food and snack-format nutrition for Gen ZYoung adults (China)2,022Disclosed as popular with Gen Z (FY2022)
Swisse GummiesSugar-free gummy formatsANZ and expansion markets2022–23No. 2 position in ANZ gummies (FY2023)
Swisse NutraPremium beauty supplement rangeExpansion markets (Asia)H1 2026New launch cited in H1 2026
Swisse EarthRange with packaging of up to 70% recycled contentANZ eco-conscious consumersc.2022ESG-led line
Sports nutrition / skin careIncluded in the ANC segment definitionAdults—Aurelia skincare discontinued in the UK (FY2024 restructuring)

Channel facts:

China, FY2025: CBEC was 82.0% of China ANC revenue. Douyin grew +71.4% (Swisse ranked No. 4), and Sam's Club grew +29.7%.

China, H1 2026: CBEC was 81.7% with +20.9% growth. Douyin grew +57.5% (Swisse now No. 3), and new retail grew +34.2%.

BNC — Baby Nutrition & Care

Brand / lineDescriptionTargetLaunch / latestFlagships and notes
Biostime super-premium IMF (Stages 1–3)Imported French-made cow-milk IMF series registered under new GBChinese urban parents, premium/super-premiumNew-GB series approved Feb–Dec 2023; transition complete Jun 2025Alpha Star was the first new-GB approval (Feb 2023); seven series approved by Dec 2023. Super-premium share: 12.1% (2022), 12.4% (2023), 13.3% (2024), 17.1% (2025), 20.6% LTM Jun 2026 (Nielsen)
Biostime HMO IMFDescribed as the first imported IMF with Human Milk Oligosaccharide in Chinese mainlandPremium parentsRolled out H1 2026Key 2026 growth driver; marketing step-up in H2 2026
Biostime goat-milk IMFImported goat-milk formulaPremium nichePending new-GB in 2023 (RMB178.6M write-off)France pharmacy goat-milk share 57.9% (GERS, LTM Jun 2026)
Biostime organic IMF (France)Organic formula sold in French pharmaciesFrench parentsOngoingFrance organic IMF pharmacy share 41.8% (LTM Jun 2026)
Biostime paediatric probioticsProbiotic sachets, powders, capsules for infants, children and expectant mothers; lactoferrin probiotics; Nasal Comfort; Super Gold ProbioticsParents (pharmacy, baby stores, online)Since 1999; continuous NPDNo. 1 in China paediatric probiotics (Kantar). Online contribution rose from 49.2% (2024) to 62.1% (2025)
Biostime kids nutritional supplementsDHA, calcium, gummies, kids nutrition powder supplementsChildren2022–2025 launchesKids Gummies launched in China and France (2022)
Good GoûtFrench organic baby food and snacksEuropean parentsAcquired c.2018Impairments: RMB97.3M (2023, with Aurelia), part of RMB124.0M (2024), RMB106.5M (2025). European restructuring in 2025
DodieFrench baby accessories and care (bottles, pacifiers); formerly diapers in ChinaParentsChina diaper business exited from 2024Part of the 2024 impairment

PNC — Pet Nutrition & Care

Brand / lineDescriptionTargetLaunch / latestFlagships and notes
Zesty PawsMulti-condition dog and cat supplements (soft chews, oral sticks, powders, fish oil, probiotics, joint and hip, skin and coat, allergy/immune, calming); NASC-certifiedUS pet parents, premiumBrand founded 2014/15; acquired Oct 2021No. 1 on Amazon (2023); No. 4 offline, 10.0% share (2023). Growth: +21.7% (2023), +12.8% (2025), +16.7% LFL (H1 2026). Distribution in more than 23,000 US stores (Jun 2026). Channels include TikTok Shop. Fish-oil launch in China (2023); pilot in UK
Solid GoldHolistic, super-premium dog and cat food (dry, wet, NutrientBoost range, toppers, bone broth), now expanding into supplementsPremium pet owners, US and ChinaAcquired Dec 2020US: channel optimisation completed 2025; returned to +6.3% LFL growth in H1 2026; e-commerce 83.1% of US sales; high-margin items 37.4% of sales (2025). China: No. 2 in online premium cat dry food; shifting to locally made supply (completion expected end-2026); first "cat-derived" probiotics range in China (H1 2026). In more than 4,000 US stores

Financial Narrative

All figures are in RMB M under IFRS, from audited annual results announcements unless noted. Operating income is defined here as profit before tax + finance costs + share of losses of associates (derived).

Income statement

Revenue CAGR FY2021–FY2025: 5.6% (derived).

Adjusted EBITDA CAGR: 2.6%.

DPS composition (HKD): - FY2021: interim 0.37 + final 0.17

  • FY2022: 0.25 + 0.38

  • FY2023: 0.44 + 0.18

  • FY2024: 0.30 + 0.05

  • FY2025: 0.19 + 0.16

Commentary on income-statement trends.

FY2021–22: the Zesty Paws step-change: FY2021 reported profit halved (net profit RMB508.5M vs RMB1,136.7M in FY2020). The drivers were RMB361.7M of non-cash losses (FX, derivative fair value, Changsha goodwill impairment) and M&A costs; adjusted net profit fell a more modest 12.4%. FY2022 revenue rose 10.6% as Zesty Paws was consolidated (North America +144.5%), but finance costs nearly doubled to RMB525.7M on US$550M of incremental acquisition debt. This began a three-year period in which interest absorbed most of EBIT.

FY2023: mix shift masks the IMF crisis: ANC surged 34.8% on post-COVID immunity demand and Swisse Plus+, while BNC fell 11.7% as China's IMF market contracted 22.9% during the new-GB transition. Adjusted EBITDA peaked at RMB2,215.5M (15.9% margin). Finance costs jumped to RMB773.5M as US base rates rose. Net current liabilities of RMB3.3bn (refinancing wall) required a going-concern statement.

FY2024: the trough: BNC fell a further 25.8%. IMF fell 24.2% as old-GB stock destocked and new products launched, with RMB178.4M of one-time launch marketing. Probiotics fell 32.3% on pharmacy-channel weakness. Goodwill and intangible impairments (Dodie, Good Goût) of RMB124.0M and FX losses of RMB176.8M pushed the reported result to a RMB53.7M loss, despite adjusted net profit of RMB541.2M.

FY2025: recovery: Revenue grew +10.0% (IMF +26.5%) and gross margin expanded 180bps to 62.4% on sourcing optimisation and PNC mix. However, the S&D ratio rose to 42.2% (ANC channel mix toward Douyin and expansion-market investment), compressing adjusted EBITDA margin to 14.3%. Reported net profit of RMB196.1M was suppressed by a RMB224.4M one-time premium on early redemption of the 13.5% notes.

H1 2026: inflection: Operating leverage, a BNC demand surge partly from competitor recalls, marketing phasing and halved finance costs drove adjusted EBITDA margin to 21.8%. Management explicitly flagged higher H2 marketing for HMO IMF and Swisse launches, so H1 margins are not a full-year run-rate. The outlook speaks of "consistent underlying full-year profitability despite macro challenges."

Balance sheet

Notes:

  • FY2025 net debt (carrying) uses cash plus RMB40M of time deposits (RMB1,709.0M).

  • The company's net debt uses gross debt at constant FX rates as at drawdown.

  • FY2025 total debt comprises bank loans RMB6,079.9M, senior notes RMB2,158.6M, guaranteed bonds RMB410.8M and LC discounting RMB244.8M.

30 June 2026: borrowings RMB7,581.6M (current RMB1,803.0M); cash plus time deposits RMB1,976.5M; company net debt RMB5,813.7M; equity RMB6,513.8M; net current liabilities RMB783.9M. The current-liability position is driven by term loans due 2027 being reclassified as current; it is addressed by the US$320M refinancing signed on 5 Aug 2026.

Balance-sheet commentary.

  • Intangibles dominate. Goodwill and intangibles of RMB12.7bn exceed equity of RMB6.0bn by 2.1x, so tangible equity is negative. This is the structural legacy of the Swisse (2015), Solid Gold (2020) and Zesty Paws (2021) acquisitions.

  • Impairments to date have hit the smaller European assets (Aurelia, Good Goût, Dodie) and the Changsha plant, not the core brands.

  • The recurring "refinancing wall" pattern is notable: net current liabilities in FY2021 and FY2023, and again at H1 2026. Each was resolved, but it signals reliance on bank refinancing cycles.

  • Inventory discipline improved markedly: days fell from 169 (FY2021) to 129 (FY2025) and 118 (H1 2026).

  • The A$104M (RMB487.9M) ATO deposit sits in prepayments and deposits. It moved to non-current deposits (RMB509.6M) at June 2026.

Cash flow

Notes:

  • FY2022 capex includes right-of-use assets.

  • FY2025 OCF is after the RMB487.9M ATO deposit outflow. Excluding it, underlying OCF would be about RMB2.0bn (derived).

H1 2026: OCF RMB1,695.1M; capex RMB38.4M; cash conversion (pre-tax cash from operations / adjusted EBITDA) 100.0%.

Buybacks: no share cancellations in FY2021–H1 2026. The FY2022 HK$75.8M of purchases were for the share award trust. Debt buybacks: US$29.8M (2022) and US$68.2M (2023) of 5.625% 2024 notes, and US$20.2M (2023) and the full US$297M (2025) of 13.5% 2026 notes.

Ratios

Notes:

  • The FY2021 ROE denominator uses FY2020 equity of RMB6,202.7M.

  • The ROIC tax rate is a notional 30% (the reported ETR is distorted by non-deductible items). Invested capital uses carrying net debt.

  • Net leverage for FY2022 is shown as 3.58x per the FY2023 announcement's restated method. The FY2022 announcement originally reported 3.68x, a methodology discrepancy.

H1 2026: net leverage 2.05x (LTM adjusted EBITDA RMB2,841.7M); gearing (borrowings / total assets) 38.9%; CCC about 76 days (20 + 118 − 62); implied annual interest margin 5.65% (vs 6.96% FY2024 and 5.96% FY2025).

Ratio commentary.

  • Returns have been structurally modest (ROIC 6–9%) because of the large acquired-intangible base. The economic return on tangible capital is far higher, given RMB303M of PP&E.

  • The defining credit metric is interest coverage, which collapsed from about 4x to 1.2x between FY2021 and FY2024 as rates rose on floating USD term debt. It is now recovering sharply: H1 2026 EBIT of about RMB1,474M (derived) against finance costs of RMB311.9M is about 4.7x.

  • Working-capital efficiency has improved by about 40 days of CCC since FY2021.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business segment revenue (CNY Mn)

Business segment revenue (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Adult Nutrition & Care (ANC)

4,209.24,559.26,144.96,696.26,946.4

Baby Nutrition & Care (BNC)

6,612.26,687.25,907.54,382.35,257.3

Pet Nutrition & Care (PNC)

726.41,529.51,874.11,973.22,149.9

Group total

11,547.812,775.913,926.513,051.714,353.6

Business segment YoY growth, reported (%)

Business segment YoY growth, reported (%)FY2022FY2023FY2024FY2025

ANC

8.334.89.03.7

BNC

1.1-11.7-25.820.0

PNC

110.622.55.39.0

Business segment share of revenue (%)

Business segment share of revenue (%)FY2021FY2022FY2023FY2024FY2025

ANC

36.435.744.151.348.4

BNC

57.352.342.433.636.6

PNC

6.312.013.515.115.0

Segment Overview

SegmentH1 2026 revenue (CNY Mn)YoY reportedYoY LFLShare of revenueSegment gross margin

ANC

3,973.1+15.5%+13.9%45.7%70.2%

BNC

3,632.5+45.2%+45.2%41.8%61.5%

PNC

1,090.3+1.0%+4.8%12.5%61.1%

Total

8,695.9+23.9%+23.7%100%65.4%

Reportable segment revenue (CNY Mn)

Reportable segment revenue (CNY Mn)FY2023FY2024FY2025

Infant formulas

4,397.53,332.44,215.8

Paediatric probiotic & kids nutritional supplements

1,213.3821.3837.3

Adult nutrition & care products

6,144.96,696.26,946.4

Other paediatric products

296.7228.6204.2

Pet nutrition & care products

1,874.11,973.22,149.9

Reportable segment results = gross profit (CNY Mn)

Reportable segment results = gross profit (CNY Mn)FY2023FY2024FY2025

Infant formulas

2,301.51,849.22,323.2

Paediatric probiotic & kids nutritional supplements

927.5596.6614.0

Adult nutrition & care products

4,030.24,351.94,719.1

Other paediatric products

123.799.778.4

Pet nutrition & care products

911.41,018.11,228.9

Reportable segment gross margin (%)

Reportable segment gross margin (%)FY2023FY2024FY2025

Infant formulas

52.355.555.1

Paediatric probiotic & kids nutritional supplements

76.472.673.3

Adult nutrition & care products

65.665.067.9

Other paediatric products

41.743.638.4

Pet nutrition & care products

48.651.657.2

Reportable segment YoY growth (%)

Reportable segment YoY growth (%)FY2024FY2025

Infant formulas

-24.226.5

Paediatric probiotic & kids supplements

-32.32.0

Adult nutrition & care

9.03.7

Other paediatric

-23.0-10.7

Pet nutrition & care

5.39.0

Revenue by Segment (x)

Segment contribution proxy (%)FY2023FY2024FY2025

ANC (GM minus S&D ratio)

27.626.225.2

BNC (GM minus S&D ratio)

18.114.217.6

PNC (GM minus S&D ratio)

6.87.510.9

Income statement (CNY Mn)

Income statement (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

11,547.812,775.913,926.513,051.714,353.6

Cost of sales

4,299.85,072.45,632.25,136.25,389.9

Gross profit

7,248.07,703.58,294.37,915.58,963.7

Selling & distribution expenses

4,971.95,235.25,599.75,569.66,229.1

Administrative expenses

695.7727.7848.5779.4837.3

Other expenses

554.3382.2336.4588.6466.0

Operating income (derived EBIT)

1,134.41,578.21,724.31,140.41,493.7

EBITDA (reported)

1,428.91,847.91,984.91,405.81,772.6

Adjusted EBITDA (company)

1,851.91,971.92,215.51,952.32,050.5

Finance costs

285.1525.7773.5920.6909.9

Profit before tax

850.21,030.9933.6196.8563.1

Income tax expense

341.7419.1351.8250.5367.0

Net profit (attributable)

508.5611.8581.8-53.7196.1

Adjusted net profit (company)

952.9731.2778.3541.2664.1

EPS basic (MYR Bn)

0.790.960.91-0.080.31

EPS diluted (MYR Bn)

0.790.950.90-0.080.31

DPS total (HKD)

0.540.630.620.350.35

Margins (%)

Margins (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

62.860.359.660.662.4

Operating (EBIT) margin

9.812.412.48.710.4

EBITDA margin (reported)

12.414.514.310.812.3

Adjusted EBITDA margin

16.015.415.915.014.3

Net margin

4.44.84.2-0.41.4

Adjusted net margin

8.35.75.64.14.6

Effective tax rate (reported)

40.240.737.7127.365.2

Growth (%)

Growth (%)FY2021FY2022FY2023FY2024FY2025

Revenue growth, reported

3.210.69.0-6.310.0

Revenue growth, LFL

—7.18.2—10.3

Adjusted EBITDA growth

-10.36.512.4-11.95.0

Income Statement and Per-Share Data

H1 metric (CNY Mn)H1 2025H1 2026Change

Revenue

7,019.28,695.9+23.9%

Gross profit (GM)

4,389.1 (62.5%)

5,686.0 (65.4%)

+29.5%

S&D expenses

2,971.33,400.7+14.5%

Finance costs

579.5311.9-46.2%

Adjusted EBITDA (margin)

1,100.7 (15.7%)

1,891.9 (21.8%)

+71.9%

Net profit

71.0610.6+760.0%

Adjusted net profit

363.0919.2+153.2%

EPS basic (MYR Bn)

0.110.95—

Interim DPS (HKD)

0.190.82

50% of adjusted net profit

Balance Sheet

Balance sheet (CNY Mn, 31 Dec)FY2021FY2022FY2023FY2024FY2025

Total assets

20,281.720,963.020,042.018,842.419,403.5

Cash & cash equivalents

2,400.12,303.71,364.31,603.91,669.0

Short-term debt (bank loans + notes, current)

3,145.5986.64,722.1863.11,078.8

Long-term debt (bank loans + notes, non-current)

6,229.88,581.64,393.48,421.87,815.3

Total debt (carrying)

9,375.39,568.39,115.59,284.98,894.1

Net debt (carrying, derived)

6,975.27,264.67,751.27,681.07,185.1

Net debt (company definition)

—7,059.87,569.47,799.47,081.2

Total equity

5,885.26,141.96,295.25,813.45,990.9

Goodwill

7,472.07,684.17,820.57,603.67,620.6

Intangible assets

5,572.45,639.35,582.45,295.05,063.9

Goodwill + intangibles

13,044.413,323.413,402.912,898.612,684.5

Inventories

2,087.72,587.72,374.81,906.71,968.1

Working capital (current assets − current liabilities)

-1,308.5724.5-3,307.8750.3680.9

Cash flow (CNY Mn)

Cash flow (CNY Mn)FY2022FY2023FY2024FY2025

Net operating cash flow

1,469.31,096.91,346.41,536.8

Capex (PP&E + intangibles)

102.591.097.394.4

Free cash flow (derived OCF − capex)

1,366.81,005.91,249.11,442.4

Dividends paid

233.6474.5281.9141.5

Interest paid

474.6750.0706.1537.2

Share purchases (award-scheme trust)

61.8000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%), net profit / average equity

8.410.29.4-0.93.3

ROA (%), net profit / year-end assets

2.52.92.9-0.31.0

ROIC (%), EBIT × (1 − 30%) / (equity + net debt)

6.28.28.65.97.9

Current ratio (x)

0.811.140.611.191.15

Debt / equity (x)

1.591.561.451.601.48

Net debt / adjusted EBITDA (x, company)

3.773.583.423.993.45

Interest coverage (x), EBIT / finance costs

3.983.002.231.241.64

Adjusted EBITDA / finance costs (x)

6.503.752.862.122.25

Asset turnover (x), revenue / year-end assets

0.570.610.690.690.74

Receivable days (company)

2421242723

Inventory days (company)

169166159150129

Payable days (company)

6479766864

Cash conversion cycle (days, derived)

12910810710988

Geographic revenue (CNY Mn)

Geographic revenue (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Chinese mainland

9,084.69,565.99,972.78,685.410,201.5

Australia & New Zealand

1,307.41,387.41,794.62,012.71,574.1

North America

499.31,220.81,498.21,621.71,747.7

Other locations (incl. HK SAR, Europe, SE Asia)

656.5601.9661.0731.9830.3

Geographic YoY growth, reported (%)

Geographic YoY growth, reported (%)FY2022FY2023FY2024FY2025

Chinese mainland

5.34.3-12.917.5

Australia & New Zealand

6.129.412.2-21.8

North America

144.522.78.27.8

Other locations

-8.39.810.713.4

Geographic share of revenue (%)

Geographic share of revenue (%)FY2021FY2022FY2023FY2024FY2025

Chinese mainland

78.774.971.666.671.1

Australia & New Zealand

11.310.912.915.411.0

North America

4.39.610.812.412.1

Other locations

5.74.64.75.65.8

Region Overview

RegionH1 2026 (CNY Mn)YoY reportedYoY LFLShare

Chinese mainland

6,462.5+30.9%+30.9%74.3%

North America

956.6+10.9%+15.5%11.0%

ANZ

771.7−3.6%−8.6%8.9%

Other

505.1+20.2%+16.8%5.8%

Segment Overview — Infant formulas

SegmentChinese mainlandANZNorth AmericaOtherTotal

Infant formulas

4,091.318.50.0106.04,215.8

Paediatric probiotics & kids supplements

822.02.21.311.8837.3

Adult nutrition & care

4,911.71,553.224.8456.76,946.4

Other paediatric

0.80.00.0203.3204.2

Pet nutrition & care

375.70.11,721.652.52,149.9

Total

10,201.5

1,574.1

1,747.7

830.3

14,353.6

Share Price & Returns

Reference pointPrice (HKD)Source

14 Mar 2025 (Franklin sale price)

about 9.64

Simply Wall St insider data

22 Apr 2026 (close, approximate)

13.82

etnet

Early Jul 2026 (post profit alert, intraday)

12.48 → 14.65

Tiger / Deep News

8 Jul 2026

14.66

Lixinger

31 Jul 2026

15.19

Lixinger

5 Aug 2026

14.49

Lixinger

23 Sep 2026

17.95

10jqka (after Moody's outlook revision)

Valuation Multiples

MultipleH&HBasis

Market cap

HK$11.59bn (about RMB10.26bn)

645.56M shares

P/E (TTM reported)

about 13.9x

TTM net profit RMB735.7M (FY2025 196.1 − H1'25 71.0 + H1'26 610.6)

P/E (TTM adjusted)

about 8.4x

TTM adjusted net profit RMB1,220.3M

EV / adjusted EBITDA (TTM)

about 5.7x

EV about RMB16.07bn (market cap + net debt RMB5,813.7M); LTM adjusted EBITDA RMB2,841.7M

EV / Sales (TTM)

about 1.0x

TTM revenue RMB16,030.3M

P/B

about 1.6x

Equity RMB6,513.8M (Jun 2026)

Dividend yield (trailing 12 months)

about 5.5%

HK$0.16 final FY2025 + HK$0.82 interim 2026

Analyst Ratings & Targets

BrokerRatingTarget price (HKD)Date

CICC

Outperform (maintained)

17.7

Apr 2026

China Merchants Securities

Strong Buy (maintained)

21.0

Apr 2026

Soochow Securities

Buy (maintained)

—

Apr 2026

Guosheng Securities

Buy (maintained)

—

Apr 2026

Huatai Securities

Buy (reiterated)

—

Jul 2026

Dividend metric

Dividend metricFY2021FY2022FY2023FY2024FY2025

Interim DPS (HKD)

0.370.250.440.300.19

Final DPS (HKD)

0.170.380.180.050.16

Total DPS (HKD)

0.540.630.620.350.35

Payout of adjusted net profit (%)

3050463830

Credit Ratings

AgencyRatingOutlookDate / note

Moody's

Ba3 CFR; senior unsecured B1 (as of 2022)

Positive (from Stable)

Downgraded from Ba2 on 1 Apr 2022; outlook revised Sep 2026

S&P Global

BB+ issuer; notes BB (as of Jan 2022)

Stable (2022)

—

Capital Instruments

InstrumentAmountCouponMaturityNotes

USD term loans (2022 / 2024 facilities)

Bank loans total RMB5,069.5M (current RMB1,308.5M)

Floating (swapped)

2027

Being refinanced by the about US$320M facility signed 5 Aug 2026; RMB300M prepaid 13 Aug 2026

New term loan + RCF

About US$320M + US$10M

—

Extended (n/d)

Signed 5 Aug 2026

Senior notes due 2028

US$300M (carrying RMB2,098.5M)

9.125%

Jul 2028

Issued Jan 2025; early redemption option embedded

Guaranteed bonds due 2027

RMB500M (carrying RMB413.6M, all current)

7.5%2027

Issued 20 Mar 2024

MYR Bn bank borrowings

Included in bank loans

Low-cost RMB

Various

Increasing share

LC discounting (Dec 2025)

RMB244.8M

—

≤180 days

Working-capital facility

Analyst Conclusions

Management guidance (H1 2026 interim, 25 Aug 2026)

Management expects "continued growth with consistent underlying full-year profitability despite macro challenges." The specific expectations are:

ANC: continued growth across China, ANZ domestic and expansion markets.

BNC: further IMF growth from HMO IMF, new-mother education and Stage 3 conversion.

PNC: an upward trajectory, with China PNC focused on locally made, high-margin product.

Costs: stepped-up H2 marketing investment.

Balance sheet: continued deleveraging.

There is no numerical guidance.

Consensus growth expectations

Broker commentary (CICC, CMS, Huatai, Soochow, Guosheng; Apr–Jul 2026) uniformly cites:

  • a "new product big year" (HMO IMF, Swisse launches);

  • accelerating deleveraging that lowers interest costs;

  • valuation upside.

Bull case

  1. Structural IMF share gains. Biostime's super-premium share rose from 12.4% (2023) to 20.6% (LTM Jun 2026), and Stage 1 / Stage 2 scan growth was +68.8% / +41.8% in H1 2026. This builds a Stage 3 pipeline that extends the IMF recovery into 2027, independent of recall effects.

  2. Earnings and deleveraging flywheel. Finance costs fell 46.2% in H1 2026, and net leverage dropped to 2.05x. A Moody's upgrade and the 2027 refinancing could cut interest further, converting more EBITDA into equity value and supporting a 50% payout. The trailing yield is about 5.5% at about 5.7x EV/EBITDA.

  3. Swisse franchise compounding. No. 1 positions in China and Australia, a US$1bn brand, Douyin rank rising from No. 4 to No. 3, and expansion markets growing 30%+ give a multi-year mid-to-high-single-digit growth runway at 70% gross margin.

Bear case

  1. Recall-driven demand is transitory. Management concedes part of the H1 2026 IMF uplift reflected competitor recalls. As Nestlé, Danone and others restore trust, IMF growth could decelerate sharply against a high 2026 base, while China's IMF market keeps shrinking (−3.5%).

  2. H1 margins overstate run-rate. The 21.8% adjusted EBITDA margin benefited from marketing phasing; FY2025's full-year margin was 14.3%. A heavy H2 2026 A&P step-up could disappoint full-year expectations.

  3. Tail risks. An adverse Federal Court outcome on the ATO matter (about A$370M+ plus interest versus the A$104M deposit), China CBEC regulatory change, and 74% revenue concentration in China could each impair equity value. Goodwill and intangibles of RMB12.7bn leave little tangible equity cushion.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Q3 2026 / 9M operating data (IMF growth durability; Swisse China channel mix)About mid-Oct to Nov 2026
Drawdown of the US$320M refinancing; further term-loan prepayments; Moody's rating actionQ4 2026 – 2027
H2 2026 marketing intensity versus margin; FY2026 results and final dividendMar 2027
Super-premium IMF share trajectory (Nielsen) as competitor recalls normaliseQuarterly
ATO matter: Federal Court and ART hearing dates; any settlement2027 onward
Solid Gold China localisation completion; Zesty Paws growth (more than 23,000 doors)End-2026
China birth-support policies and CBEC regulatory changesOngoing
RMB500M 7.5% bonds due 2027 repayment / refinancing2,027

Concluding analyst verdict

H&H enters late 2026 at a genuine inflection after a bruising 2022–2024 period. In those years debt-funded pet M&A, a three-year China IMF re-registration upheaval, rising USD rates and a revolving door at the CEO office combined to drive reported earnings to a loss in FY2024.

The evidence for repair is now strong and mostly verifiable in audited and reviewed filings:

  • revenue growth of +10.0% (FY2025) accelerating to +23.9% (H1 2026);

  • gross margin at 65.4%;

  • finance costs halved;

  • net leverage cut from 3.99x to 2.05x in 18 months;

  • the dividend payout restored to 50%.

The quality of the recovery is mixed but better than sceptics allow. Swisse's leadership in China and Australia, and Zesty Paws' omni-channel scaling, are organic, multi-year achievements. Biostime's share gains began well before the 2026 recalls: share rose from 13.3% to 17.1% during 2025. The recalls amplified, rather than created, the IMF rebound. However, the H1 2026 margin peak is partly a phasing artefact. Investors should anchor on full-year adjusted EBITDA margins in the high-teens rather than above 21%, and expect IMF growth to moderate meaningfully in 2027.

At roughly 5.7x EV/LTM adjusted EBITDA, about 8.4x adjusted P/E and a trailing yield of about 5.5% (dossier estimates at HK$17.95), the market still prices H&H as a levered, China-concentrated consumer name carrying an unresolved A$370M+ tax dispute.

  • controlling-shareholder governance;

  • a rotating-CEO structure without a single accountable leader;

  • negative tangible equity;

  • CBEC regulatory dependency.

On balance, the risk-reward appears constructive. Continued deleveraging toward about 1.5x, a potential Moody's upgrade from Ba3, and sustained Swisse compounding offer equity upside, while a dividend near 50% payout pays investors to wait. The two decisive monitorables are the durability of IMF growth through 2027 and the Federal Court outcome on the ATO dispute. A loss on the latter, without settlement, is the single largest identifiable downside to this view.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / backgroundCommittees

Mr. Luo Fei

Chairman, Executive Director

Co-founder (1999); CEO until Mar 2019; standing member of the CEO Office; controlling-shareholder interest of 67.18%

Chair, Nomination Committee

Mr. Wang Yidong ("Jason Wang")

Executive Director; Group Chief Financial & Operating Officer

Standing member of the CEO Office; holds 0.41% (Dec 2025)

—

Mrs. Laetitia Albertini (née Garnier)

Non-executive Director

Joined 2010; ED from 26 Mar 2018; CEO 19 Mar 2019 – 31 Dec 2022; NED from 1 Jan 2023 (NED fee RMB800k p.a. per media reports); holds 0.34%

—

Dr. Zhang Wenhui

Non-executive Director

——

Mr. Luo Yun

Non-executive Director

Co-founder; brother of Luo Fei; associated with the controlling holding structure

Audit Committee member

Mrs. Mingshu Zhao Wiggins

Non-executive Director

Appointed by 1 Jan 2024 (board list)

—

Mr. Tan Wee Seng

Independent NED

Long-serving INED

Audit, Nomination

Mrs. Lok Lau Yin Ching

Independent NED

Long-serving INED

—

Professor Ding Yuan

Independent NED

Accounting / financial expertise

Chair, Audit Committee

Executive Leadership Team

NameRoleNotes

Akash Bedi

Regional CEO, North America, Europe, India & Middle East; first rotating Group CEO (from 1 Dec 2023)

Former Chief Strategy & Operations Officer; Acting CEO Oct 2022 – Aug 2023; holds 0.26%

Nicholas (Nick) Mann

Regional CEO, Asia, Australia & New Zealand; second in the rotation

Holds 0.26%

Li Fengting (Suceka Lee)

Regional CEO, China; third in the rotation

Holds 0.30%

Zhang Qizhang (Victor Zhang)

Chief People Officer; standing CEO Office member

Holds 0.30%

Wang Yidong (Jason Wang)

CFO & COO

See board

Steve Ball

CEO, North America (PNC) / former Zesty Paws CEO

—

Board & Management Changes

DateChange

26 Sep 2022

Announced Albertini would cease as CEO on 31 Dec 2022; Bedi named Acting CEO from 1 Oct 2022

28 May 2023

Camillo Pane (ex-CEO of Coty Inc.; previously Reckitt Benckiser Consumer Health) appointed CEO effective 1 Sep 2023 for a three-year term

20 Nov 2023

Pane and the company "mutually agreed to separate"; CEO Office with rotating CEO established as a "permanent fixture"

26 Mar 2024

Executive Committee dissolved; functions absorbed by the CEO Office

Major Shareholders

HolderShares% of issuedDate / source

Coliving Holdings Ltd (via Flying Company Ltd / Coliving Ltd; UBS Trustees (BVI) as trustee) — Luo family

432,000,00066.92

SDI filing 3 Apr 2025; aktien.guide 10 Apr 2026

Luo Fei (aggregate interest incl. above)

433,678,19867.18

SDI 3 Apr 2025

Templeton Asset Management / Franklin Resources

31,287,2814.85

14 Mar 2025

Fidelity International

13,123,0002.03

31 Mar 2026

The Vanguard Group

6,437,9881.00

Simply Wall St (date n/d)

Dimensional Fund Advisors

3,691,000 – 5,094,073

0.57 – 0.79

30 Apr 2026 / earlier (sources differ)

E Fund Management

4,679,0000.72

31 Dec 2025

Bank of Communications Schroder Fund Mgmt

4,537,1010.70

Simply Wall St

BlackRock

2,781,5220.43

Simply Wall St

Southbound Stock Connect (aggregate, SH + SZ)

about 78–86M

about 12.1 – 13.4

Lixinger, Jul–Aug 2026

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs H&H

China IMF (super-premium)

Feihe (China Feihe, 6186.HK)

Domestic market leader across tiers; also sourced ARA oil from the Cabio supplier implicated in 2026

China IMF

Nestlé (Illuma, Wyeth, NAN)

Global leader; 2026 recall damaged its China position

China IMF

Danone (Aptamil, Nutrilon)

Premium imported leader; 2026 recalls in some markets

China IMF

a2 Milk Company

Premium A2-protein niche

China IMF

Junlebao, Yili (Pro-Kido / Jinlingguan), Mengniu (Reeborne)

Domestic scale players

China IMF

Abbott, Friesland (Friso)

Imported premium brands

China / ANZ VHMS

By-health (300146.SZ)

Leading Chinese domestic VHMS company, strong offline / pharmacy

China / ANZ VHMS

Blackmores (Kirin Holdings)

Australian VHMS rival in ANZ and China CBEC

China / ANZ VHMS

Haleon (Centrum, Caltrate)

Global multinational VHMS

China / ANZ VHMS

Amway (Nutrilite)

Direct-selling VHMS leader

China / ANZ VHMS

Bayer (Elevit, Berocca), Herbs of Gold, Nature's Way, GNC, Move Free (Reckitt)

Category specialists

Paediatric probiotics

Culturelle (i-Health / DSM-Firmenich), BioGaia, Life-Space, domestic pharmacy brands

H&H (Biostime) is No. 1 in China per Kantar

US pet supplements

Nutramax (Cosequin, Dasuquin), PetHonesty, Native Pet, Purina (Pro Plan Veterinary Supplements), NaturVet, VetriScience

Zesty Paws No. 1 on Amazon (2023); No. 4 offline (10.0%, 2023)

US / China pet food

Nestlé Purina, Mars Petcare (Royal Canin), General Mills (Blue Buffalo), Hill's (Colgate), Orijen / Acana (Champion, Mars); China: Myfoodie (Guai Bao), Gambol (Fregate), Royal Canin China

Solid Gold is No. 2 in China online premium cat dry food; small share in the US

Competitor Detail

MetricH&H (FY2025)

Revenue

RMB14.35bn

Revenue growth

+10.0%

Gross margin

62.4%

Adjusted EBITDA margin

14.3% (H1 2026: 21.8%)

R&D intensity

1.5%

Balance sheet

Net leverage 3.45x (2.05x Jun 2026)

Recent Developments

There were no layoffs, product safety recalls of H&H's own products, or regulatory sanctions against the company in public sources during the window.

Company Snapshot

$1,996.3M

Revenue

2,800

Employees

1999

Founded

Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Category leadership in two China-scale franchises. Swisse is No. 1 in China overall VHMS (Kantar, FY2025) and No. 1 in Australian VMS (IQVIA). Biostime is No. 1 in paediatric probiotics (Kantar) with a 20.6% super-premium IMF share (Nielsen, LTM Jun 2026).
  • Structurally high gross margins. Group GM was 62.4% (FY2025) and 65.4% (H1 2026); ANC segment GM was 70.2% in H1 2026.
  • Strong cash conversion and asset-light model. H1 2026 cash conversion was 100.0%; FY2025 capex was only RMB94.4M (0.7% of revenue); PP&E is RMB302.8M.
  • Diversification across life stages and species. No business segment exceeds 49% of revenue (FY2025: ANC 48.4%, BNC 36.6%, PNC 15.0%), cushioning birth-rate exposure.
  • Proven channel agility. Douyin grew +71.4% in FY2025 and +57.5% in H1 2026; CBEC grew +18.9% and +20.9%.
  • Rapid deleveraging capability. Net leverage fell from 3.99x (Dec 2024) to 2.05x (Jun 2026), and RMB / RMB-hedged debt now makes up 97.8% of borrowings.

Weaknesses

  • Heavy China concentration. Chinese mainland was 74.3% of H1 2026 revenue, up from 66.6% in FY2024.
  • High A&P and S&D intensity. The S&D ratio was 42.2% of revenue in FY2025; ANC advertising and marketing reached 35.2% of ANC revenue.
  • Large acquired-intangible base and low returns. Goodwill and intangibles of RMB12.7bn are 2.1x equity, and ROIC has been 6–9%.
  • Leadership instability. Three CEO changes in 12 months during 2022–23, ending in a rotating-CEO model with no single accountable CEO.
  • Persistent European value destruction. Cumulative impairments on Aurelia, Good Goût and Dodie of RMB134.5M (2022), RMB97.3M (2023), RMB124.0M (2024) and RMB106.5M (2025).
  • Low R&D intensity. R&D was 1.2–1.9% of revenue, which limits proprietary science differentiation.

Opportunities

  • IMF share capture after the 2026 multinational recalls. China IMF grew +58.0% in H1 2026 against a market down 3.5%.
  • HMO IMF premiumisation. The first imported HMO IMF in China launched in H1 2026.
  • Ageing-population cellular nutrition. Swisse Plus (NAD+) grew +18.6% in H1 2026.
  • Expansion markets. Asian expansion markets grew +53.9% LFL (FY2025) and +32.6% (H1 2026), yet are still only 7.8% of ANC.
  • Credit upgrade and refinancing savings. Moody's outlook is Positive (Sep 2026); the implied interest margin is 5.65% and falling; H1 2026 finance costs fell 46.2%.
  • Higher shareholder payouts. The interim payout returned to 50% (HK$0.82).

Threats

  • ATO tax dispute. After the objection decision, primary tax is A$208.1M and the penalty A$104.0M, plus interest. Total exposure is about A$370M+ (derived, before interest updates) against an A$104M deposit already paid.
  • China CBEC and health-food regulation. A change to the CBEC positive list or tax treatment would hit about 82% of China ANC revenue.
  • Demographics. Continued decline in Chinese births pressures the IMF category; market retail scan sales were −3.5% in LTM Jun 2026.
  • Fading recall-driven demand. Part of the 2026 IMF uplift reflected "shifts in consumer demand amid recent industry developments" (company), which may normalise as competitors recover.
  • Tariffs and geopolitics. US–China tariffs disrupted Solid Gold China (PNC China revenue −37.7% in H1 2026).
  • FX volatility. Non-cash FX and derivative losses were RMB237.3M in H1 2026, and RMB appreciation affects USD-swapped debt valuations.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
10 Apr 2025Q1 2025 operating data: revenue RMB3,169.9M, +10.4%Recovery begins, led by China IMF
10 Apr 2025ATO issues amended assessments to BHA (A$234.5M tax, A$55.2M interest, A$117.3M penalty)Material contingent liability (about A$407M total)
1 Apr 2025Director share-award vesting and transactions (Albertini, Tan, Lok, Ding, Zhao Wiggins)Routine
Jun 2025BHA lodges formal objection to the ATO assessmentsDispute process
Jun 2025New-GB IMF transition completedRemoves a three-year BNC overhang
Mid-2025Strategic decision to deprioritise ANZ corporate daigouANZ revenue headwind; quality upgrade
4 Jul 2025ATO requires an A$104M deposit (announcement)Liquidity drain
15 Jul 2025A$104M (RMB487.9M) deposit paidCash outflow absorbed
26 Aug 2025H1 2025 results: revenue +4.9%, net profit RMB71.0M, interim DPS HK$0.19Profit depressed by RMB224.4M note-redemption premium
2025 (during year)Full repurchase and redemption of US$297M 13.5% notes due 2026Coupon burden removed
Oct 2025Interim dividend HK$0.19 paid–
18 Nov 20259M 2025 operating data: revenue RMB10,805.3M, +12.0%; Q3 hit by channel shift from normal trade to CBECMomentum maintained
23 Dec 2025Share options and awards granted to executives (Bedi, Li, Wang, Zhang, Mann)Management alignment
Dec 2025 – Jan 2026Nestlé infant formula recall (cereulide from ARA oil) begins, spreading to 50–60+ countries; Danone and Lactalis follow (22 Jan 2026)Major competitive dislocation
12 Feb 2026China SAMR orders mandatory cereulide testing for IMF makersRegulatory tightening favours trusted brands
Feb – Mar 2026About RMB500M voluntary prepayment of the USD term loanDeleveraging
3 Mar 2026Positive profit alert / FY2025 operational update–
24 Mar 2026FY2025 results: revenue +10.0%, net profit RMB196.1M, adjusted net profit +22.7%, final DPS HK$0.16Return to profit
10 Apr 20262025 Annual Report and 2025 Sustainability Report published–
22 Apr 2026Q1 2026 operating data: revenue about RMB4.26bn, +33.8%; gross debt down more than RMB300M; cash above RMB2.1bnStrong beat (CICC, Soochow, Guosheng, CMS reiterate positive ratings)
15 May 2026AGMRoutine
3 Jul 2026ATO objection decision: substantially disallowed, but primary tax cut to A$208.1M and penalty to A$104.0MDispute escalates to litigation
5 Jul 2026Positive profit alert: H1 adjusted net profit up more than 100%, reported net profit up more than 700%; super-premium IMF share 20.0% vs 14.6%Shares +10% to HK$12.48, then +19% and +9% over the following sessions
10 Jul 2026BHA files Notice of Appeal in the Federal Court of Australia (tax assessment)Litigation commenced
16 Jul 2026BHA applies to the Administrative Review Tribunal (penalties and interest)Parallel review
17 Jul 2026Final FY2025 dividend HK$0.16 paid–
5 Aug 2026New term loan facility signed (about US$320M plus US$10M RCF) to refinance 2027 maturitiesRemoves the refinancing wall
13 Aug 2026RMB300M voluntary USD term-loan prepaymentDeleveraging
25 Aug 2026H1 2026 results: revenue +23.9%, net profit RMB610.6M, adjusted EBITDA margin 21.8%, net leverage 2.05x, interim DPS HK$0.82Record half
Sep 2026Moody's revises outlook to Positive from StableCredit-upgrade path; shares +3.4% to HK$17.95 (23 Sep)
12 Oct 2026 (scheduled)Interim dividend HK$0.82 payable (record date 16 Sep 2026)Cash return about RMB459.6M

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Revenue rose from CNY 11,547.8 Mn in FY2021 to CNY 14,353.6 Mn in FY2025.
Health and Happiness (H&H) International Holdings Limited — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue11,547.812,775.913,926.513,051.714,353.6
Cost of sales4,299.85,072.45,632.25,136.25,389.9
Gross profit7,2487,703.58,294.37,915.58,963.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. H&H FY2025 Annual Results Announcement (24 Mar 2026) (www1.hkexnews.hk)
  2. H&H H1 2026 Interim Results Announcement (25 Aug 2026) (www1.hkexnews.hk)
  3. H&H FY2023 Annual Results Announcement (26 Mar 2024) (www1.hkexnews.hk)
  4. H&H FY2022 Annual Results Announcement (21 Mar 2023) (www1.hkexnews.hk)
  5. H&H FY2024 Annual Results Announcement (25 Mar 2025) (www1.hkexnews.hk)
  6. H&H FY2021 Annual Results Announcement (22 Mar 2022) (www1.hkexnews.hk)
  7. H&H H1 2025 Interim Results (26 Aug 2025) (www1.hkexnews.hk)
  8. H&H FY2025 operational update (3 Mar 2026) (www1.hkexnews.hk)
  9. H&H 2025 Annual Report (10 Apr 2026) (hkexnews.hk)
  10. H&H Interim Report 2026 (hkexnews.hk)
  11. CEO appointment (Pane), 28 May 2023 (www1.hkexnews.hk)
  12. Cessation of CEO / CEO Office, 20 Nov 2023 (www1.hkexnews.hk)
  13. Cessation of CEO (Albertini), 26 Sep 2022 (www1.hkexnews.hk)
  14. List of Directors (effective 1 Jan 2024) (www1.hkexnews.hk)
  15. NutraIngredients-Asia on the rotating CEO model (Dec 2023) (nutraingredients.com)
  16. Just Food on the Zesty Paws deal (just-food.com)
  17. Houlihan Lokey on the Zesty Paws closing (hl.com)
  18. B Lab, H&H Group B Corp profile (bcorporation.net)
  19. Moody's Ba3 downgrade (Apr 2022), via HSTong (hstong.com)
  20. S&P BB+ affirmation webinar (spglobal.com)
  21. Moody's outlook revised to Positive (Sep 2026), via 10jqka (stock.10jqka.com.cn)
  22. Q1 2026 operating data, via CLS (cls.cn)
  23. Broker ratings summary (Apr 2026), via CLS (cls.cn)
  24. H1 2026 profit alert and price reaction (Tiger) (itiger.com)
  25. Huatai Buy reiteration (Tiger) (itiger.com)
  26. Lixinger 1112 market data (lixinger.com)
  27. etnet disclosure of interests (etnet.com.hk)
  28. aktien.guide ownership (aktien.guide)
  29. Simply Wall St ownership (simplywall.st)
  30. Monthly return, Jan 2026 (Tiger) (itiger.com)
  31. 9M 2025 operating data (Reuters via Tiger) (itiger.com)
  32. Cbonds, 9.125% 2028 notes (cbonds.ru)
  33. Davis Polk, RMB500M 7.5% bonds due 2027 (davispolk.com)
  34. Nestlé recall and China IMF market size (Reuters via BBC.bm) (bbc.bm)
  35. China SAMR cereulide testing (Bloomberg) (bloomberg.com)
  36. Food Safety News, Nestlé recall expansion (foodsafetynews.com)
  37. Jiemian, management pay and targets (jiemian.com)
  38. TipRanks revenue / employee data (tipranks.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.